Anna Annunziata

Dr. Anna Annunziata


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAnna Annunziata
Anna Annunziata
AMAngela irene Mirizzi
Angela irene Mirizzi
Antonietta CoppolaAntonietta Coppola
Antonietta Coppola
MVMaria Rosaria Valentino
Maria Rosaria Valentino
RSRosa Saggio
Rosa Saggio
GFGiuseppe Fiorentino
Giuseppe Fiorentino
Background: DMD causes progressive respiratory muscle weakness and chronic alveolar hypoventilation requiring ventilatory support. While nocturnal non-invasive ventilation (NIV) is the standard care, daytime ventilation is often provided with prolonged use of nasal–oronasal masks. These interfaces can cause skin injury, air leaks, and reduced adherence. Mouthpiece ventilation (MPV) provides on-demand pressure support without an interface and may be an alternative for intermittent daytime ventilation. Objective: To assess the feasibility, safety, and clinical impact of MPV as an adjunct to nocturnal NIV in patients with DMD. Methods: Six patients with DMD and chronic respiratory failure on nocturnal NIV were enrolled in a 30-day observational pilot study. After training, participants used MPV during daytime. Clinical assessment, arterial blood gases, and quality of life evaluated with the S3-NIV questionnaire were performed at baseline (T0) and after 30 days (T1). Results: All patients tolerated MPV well, with mean daily use of >16 h. PaCO2 decreased in all patients (from 49.7 ± 7.1 to 43.5 ± 5.7 mmHg; p = 0.031); 4/6 were normocapnic at T1, whereas hypercapnia persisted in two. S3-NIV scores improved from 2.53 ± 0.69 at T0 to 4.87 ± 0.91 at T1 (p = 0.031). Patients reported improved performance of daily activities and better psychological well-being. No MPV-related adverse events occurred. Conclusions: MPV was feasible, safe, and well tolerated as an adjunct to nocturnal NIV in this small series of patients with DMD over 30 days. Given the small sample and short follow-up, no firm conclusions can be drawn; larger studies with longer follow-up are needed to confirm these findings and define the optimal role of MPV in DMD respiratory management.

6 September 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AAAnna Annunziata
Anna Annunziata
FSFrancesca Simioli
Francesca Simioli
GPGiorgio Emanuele Polistina
Giorgio Emanuele Polistina
AGAnna Michela Gaeta
Anna Michela Gaeta
MCMaria Cardone
Maria Cardone
GFGiuseppe Fiorentino
Giuseppe Fiorentino
Introduction: Myotonic dystrophies (DM) are progressive genetic disorders with multisystemic involvement, particularly affecting the muscular, respiratory, and neuropsychological systems. Myotonic dystrophy type 1 (DM1), or Steinert’s disease, may lead to severe respiratory complications, including sleep-disordered breathing and hypercapnia, often requiring noninvasive ventilation to manage respiratory failure. However, adherence to NIV remains a major challenge, often influenced by cognitive and psychological factors such as apathy and depression. This study aims to investigate the presence of depression and SDB in patients with DM1 initiating NIV, and to evaluate factors influencing adherence to ventilatory support. Materials and Methods: We selected 13 adult patients (≥18 years) with diagnosis of Steinert’s disease with respiratory impairment who needed to start respiratory support. Dysphagia was assessed in all patients at baseline by a videofluoroscopic swallow study. Beck’s Depression Inventory II was administered for measuring the severity of depression. The Montreal Cognitive Assessment was used as a screening tool to detect signs of neurocognitive disorders. We evaluated adherence to NIV. Results: The study population presented with sleep-disordered breathing, as indicated by a median apnea–hypopnea index (AHI) of 24 events per hour (IQR: 14.2–34.5) and an oxygen desaturation index (ODI) of 25 events per hour (IQR: 18–33). Adherence to NIV was obtained in seven patients. No difference in baseline lung function was observed. Adherent subjects had moderate hypercapnia at baseline; pCO2 was 52 vs. 49 mmHg. Non-adherent patients showed a higher prevalence of depression with a median BDI-II score of 18 vs. 6 in adherent patients. The findings highlight that psychological factors, especially depression, play a crucial role in adherence to NIV. Interestingly, depression was not linked to initial respiratory measurements but showed a significant association with nocturnal oxygen desaturation. This suggests that relying solely on clinical and respiratory assessments may not be adequate to predict or improve treatment adherence. Conclusions: Incorporating psychological evaluations and addressing mental health issues, such as depression, are essential steps to enhance NIV compliance and overall DM1 patient outcomes. A multidisciplinary approach combining respiratory and psycho-emotional interventions is crucial for effective disease management.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
AAAnna Annunziata
Anna Annunziata
MVMaria Rosaria Valentino
Maria Rosaria Valentino
SFSimioli Francesca
Simioli Francesca
ACAntonietta Coppola
Antonietta Coppola
CRCauteruccio Rosa
Cauteruccio Rosa
GFGiuseppe Fiorentino
Giuseppe Fiorentino
The standard treatment for patients with neuromuscular respiratory failure is non-invasive ventilation (NIV) as non-invasive ventilation support-setting (NVS). NVS is administered through a nasal or face mask and/or mouthpiece with the potential to cause nasal ulcers, discomfort, resulting in poor compliance. Intermittent abdominal pressure ventilation (IAPV) is a positive pressure ventilation technique that works with abdominal compressions. It has been known since 1938; however, for many years, it was out of production. In recent years, a new device has been produced that has captured the attention to this old respiratory support technique. IAPV was proposed as an alternative to NIV to our patients affected by neuromuscular disease. We considered fourteen patients with respiratory failure secondary to a neuromuscular disease (4 Steinert disease, 4 Duchenne dystrophy, and 6 Amyotrophic Lateral Sclerosis) intolerant to daytime NIV. We performed comparison of gas exchange and respiratory parameters at baseline after 60’ without ventilation in spontaneous breathing and after 1 hour during IAPV. Furthermore, we evaluated survival, adherence to IAPV and quality of life (QoL) after one year. All patients, two years later, are still using intermittent abdominal ventilation. Conclusion: Intermittent positive abdominal mechanical ventilation can be a valid alternative to noninvasive mechanical ventilation with a nasal or face mask. It improves gas exchange, symptoms, and quality of life, decreases the incidence of pneumonia, and can avert the need for intubation and tracheotomy.